公开(公告)号：EP3252039A4

公开(公告)日：2018-07-25

申请号：EP16742705

申请日：2016-01-25

申请人： BEIJING AN JIAN XI BIO MEDICAL TECH CO LTD

发明人： BEIJING AN JIAN XI BIO-MEDICAL TECHNOLOGY CO LTD

IPC分类号： C07D209/26 ,  A61K9/00 ,  A61K31/216 ,  A61K31/337 ,  A61K31/405 ,  A61K31/635 ,  A61K31/661 ,  A61K31/704 ,  A61K45/06 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  C07C317/44

CPC分类号： C07D209/26 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/216 ,  A61K31/337 ,  A61K31/405 ,  A61K31/635 ,  A61K31/661 ,  A61K31/704 ,  A61K45/06 ,  C07C317/44 ,  C07C2602/08

摘要： Disclosed are a compound as shown by the following formula 1, and a pharmaceutically acceptable salt, an ester, a hydrate and an organic solvate thereof. In the formula (1), the groups R 1 to R 17 are independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, C 1 -C 8 alkyl, C 1 -C 8 alkoxy, carbonyl, hydroxyl, amino, azido, carboxyl and C 1 -C 8 alkylsulfinyl, respectively; and X is a carbon or nitrogen atom; Y is selected from the following groups: a single bond, C 1 -C 8 alkylene, C 6 -C 20 arylene and C 4 -C 20 heteroarylene; and n is an integer from 5 to 20. Also provided in the present invention are a pharmaceutical composition containing the compound, and use thereof in the field of tumor therapy.